NAT10 and urinary bladder cancer: To further validate the biological function of NAT10 in bladder cancer cells, we exogenously expressed NAT10 in 5637 cells, which had low NAT10 expression, using pICE‐FLAG‐NAT10‐siR‐WT (NAT10) or pICE‐FLAG‐NAT10‐siR‐G641E (NAT10‐mutant, mutated conserved glycine residue 641 to glutamate, which impaired the acetyl‐CoA binding structure of NAT10).19